Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Screening with tumor markers: critical issues.

J E Roulston1

  • 1Royal Infirmary, Edinburgh, Scotland, UK. j.e.roulston@ed.ac.uk

Molecular Biotechnology
|March 6, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Markers of tumor burden : an overview.

Methods in molecular medicine·2011
Same author

Serum amylase isoenzymes in patients undergoing operation for ruptured and non-ruptured abdominal aortic aneurysm.

Journal of vascular surgery·1999
Same author

Novel tumour markers: a diagnostic role in pancreatic cancer?

British journal of cancer·1994
Same author

Serological markers for metastatic breast cancer.

Disease markers·1993
Same author

The prognostic value of early CA125 serum assay in epithelial ovarian carcinoma.

British journal of cancer·1993
Same author

The effect of surgery on the serum concentration of CA125 in epithelial ovarian cancer.

Annals of clinical biochemistry·1993
Same journal

Applications of Recombinant DNA Technology in Medicine: A Comprehensive Review.

Molecular biotechnology·2026
Same journal

Optimizing miRNA Loading into Platelet Exosomes via Electroporation: A Comparative Analysis of Buffer Systems and Voltage Parameters for Enhanced Targeted Drug Delivery.

Molecular biotechnology·2026
Same journal

Regulation of Goat Milk Protein Synthesis: Genetic Architecture, Signalling Pathways, and Omics Insights.

Molecular biotechnology·2026
Same journal

Cloning and Functional Characterization of AhyAP-T65Lig, an ATP-Dependent DNA Ligase from Trabzonvirus AP-T65.

Molecular biotechnology·2026
Same journal

Overexpression of the ATP-Citrate Lyase Gene Enhances Ganoderic Acid Biosynthesis in Ganoderma lingzhi.

Molecular biotechnology·2026
Same journal

CRISPR/Cas9 Mediated Genome Editing for Enhancing Abiotic Stress Tolerance in Rice: An Omics Guided Perspective.

Molecular biotechnology·2026
See all related articles

Tumor markers often show early promise but fail in extended trials, limiting their use in cancer screening. Misapplication and misunderstanding of their potential value lead to flawed studies and clinical context issues.

Area of Science:

  • Oncology
  • Biomarkers
  • Clinical Trials

Background:

  • Tumor markers have historically shown significant potential in cancer diagnostics.
  • However, many markers fail to meet expectations in larger, extended clinical trials.
  • This discrepancy highlights issues in their application and interpretation.

Purpose of the Study:

  • To review the literature on tumor marker utility.
  • To place the role of tumor markers in clinical context.
  • To explain how misapplication leads to misunderstanding of their value.

Main Methods:

  • Literature review of studies on tumor markers.
  • Analysis of early promise versus extended trial outcomes.
  • Examination of theoretical basis and common misunderstandings.

Related Experiment Videos

Main Results:

  • Many tumor markers, despite high specificity, are not suitable for cancer screening.
  • Early promising results for tumor markers are frequently not replicated in subsequent trials.
  • Misapplication and flawed study designs contribute to the misunderstanding of marker potential.

Conclusions:

  • The clinical utility of tumor markers requires careful evaluation beyond initial promise.
  • Understanding the theoretical basis and avoiding misapplication is crucial for valid studies.
  • Clarifying the role of tumor markers can prevent misunderstanding and improve their appropriate use.